A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Who May Qualify: - Subject must be 18 years of age or older - Must have MGFA clinical classification Grades 2-4A at time of screening - Subject must have clinically active disease and requiring ongoing therapy for GMG - MG-ADL score 6 and QMG score \>10 at screening - GMG specific autoantibodies must be above the reference laboratory ULN Who Should NOT Join This Trial: - Subject is pregnant or breastfeeding - Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion - Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager - Previous thymectomy within 6 months of screening - Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator Always talk to your doctor about whether this trial is right for you.